Clare Oni1, Sheryl Mitchell2, Katherine James3, Wan-Fai Ng4, Bridget Griffiths2, Victoria Hindmarsh2, Elizabeth Price5, Colin T Pease6, Paul Emery6, Peter Lanyon7, Adrian Jones7, Michele Bombardieri8, Nurhan Sutcliffe8, Costantino Pitzalis8, John Hunter9, Monica Gupta9, John McLaren10, Annie Cooper11, Marian Regan12, Ian Giles13, David Isenberg13, Vadivelu Saravanan14, David Coady15, Bhaskar Dasgupta16, Neil McHugh17, Steven Young-Min18, Robert Moots19, Nagui Gendi20, Mohammed Akil21, Francesca Barone22, Ben Fisher22, Saaeha Rauz22, Andrea Richards23, Simon J Bowman24. 1. Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, simon.bowman@uhb.nhs.uk. 2. Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust. 3. Interdisciplinary Computing and Complex BioSystems Research Group, School of Computing Science, Newcastle University, Newcastle. 4. Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine & Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, Newcastle upon Tyne. 5. Rheumatology Department, Great Western Hospitals NHS Foundation Trust, Swindon. 6. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds. 7. Rheumatology Department, Nottingham University Hospital, Nottingham. 8. Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, London. 9. Rheumatology Department, Gartnavel General Hospital, Glasgow. 10. Rheumatology Department, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy. 11. Rheumatology Department, Royal Hampshire County Hospital, Winchester. 12. Rheumatology Department, Royal Derby Hospital, Derby. 13. Rheumatology Department, University College London Hospitals NHS Foundation Trust, London. 14. Rheumatology Department, Queen Elizabeth Hospital, Gateshead. 15. Rheumatology Department, Sunderland Royal Hospital, Sunderland. 16. Rheumatology Department, Southend University Hospital, Southend. 17. Rheumatology Department, Royal National Hospital for Rheumatic Diseases, Bath. 18. Rheumatology Department, Portsmouth Hospitals NHS Trust, Portsmouth. 19. Rheumatology Department, Aintree University Hospitals, Liverpool. 20. Rheumatology Department, Basildon Hospital, Basildon. 21. Rheumatology Department, Royal Hallamshire Hospital, Sheffield. 22. Centre for Translational Inflammation Research, University of Birmingham, Birmingham and. 23. Department of Oral Medicine, Birmingham Dental Hospital, Birmingham, UK. 24. Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham.
Abstract
OBJECTIVE: To identify numbers of participants in the UK Primary Sjögren's Syndrome Registry (UKPSSR) who would fulfil eligibility criteria for previous/current or potential clinical trials in primary SS (pSS) in order to optimize recruitment. METHODS: We did a retrospective analysis of UKPSSR cohort data of 688 participants who had pSS with evaluable data. RESULTS: In relation to previous/current trials, 75.2% fulfilled eligibility for the Belimumab in Subjects with Primary Sjögren's Syndrome study (Belimumab), 41.4% fulfilled eligibility for the Trial of Remicade in primary Sjögren's syndrome study (Infliximab), 35.4% for the Efficacy of Tocilizumab in Primary Sjögren's Syndrome study (Tocilizumab), 31.6% for the Tolerance and Efficacy of Rituximab in Sjögren's Disease study (Rituximab), 26.9% for the Trial of anti-B-cell therapy in pSS study (Rituximab) and 26.6% for the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome study (Abatacept). If recent measures of outcome, such as the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score ⩾5 (measure of patient symptoms) and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ⩾5 (measure of systemic disease activity) are incorporated into a study design, with requirements for an unstimulated salivary flow >0 and anti-Ro positivity, then the pool of eligible participants is reduced to 14.3%. CONCLUSION: The UKPSSR identified a number of options for trial design, including selection on ESSDAI ⩾5, ESSPRI ⩾5 and serological and other parameters.
OBJECTIVE: To identify numbers of participants in the UK Primary Sjögren's Syndrome Registry (UKPSSR) who would fulfil eligibility criteria for previous/current or potential clinical trials in primary SS (pSS) in order to optimize recruitment. METHODS: We did a retrospective analysis of UKPSSR cohort data of 688 participants who had pSS with evaluable data. RESULTS: In relation to previous/current trials, 75.2% fulfilled eligibility for the Belimumab in Subjects with Primary Sjögren's Syndrome study (Belimumab), 41.4% fulfilled eligibility for the Trial of Remicade in primary Sjögren's syndrome study (Infliximab), 35.4% for the Efficacy of Tocilizumab in Primary Sjögren's Syndrome study (Tocilizumab), 31.6% for the Tolerance and Efficacy of Rituximab in Sjögren's Disease study (Rituximab), 26.9% for the Trial of anti-B-cell therapy in pSS study (Rituximab) and 26.6% for the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome study (Abatacept). If recent measures of outcome, such as the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score ⩾5 (measure of patient symptoms) and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ⩾5 (measure of systemic disease activity) are incorporated into a study design, with requirements for an unstimulated salivary flow >0 and anti-Ro positivity, then the pool of eligible participants is reduced to 14.3%. CONCLUSION: The UKPSSR identified a number of options for trial design, including selection on ESSDAI ⩾5, ESSPRI ⩾5 and serological and other parameters.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: R J Barry; N Sutcliffe; D A Isenberg; E Price; F Goldblatt; M Adler; A Canavan; J Hamburger; A Richards; M Regan; K Gadsby; S Rigby; A Jones; R Mathew; D Mulherin; A Stevenson; P Nightingale; S Rauz; S J Bowman Journal: Rheumatology (Oxford) Date: 2008-06-04 Impact factor: 7.580
Authors: Simon J Bowman; Yvan St Pierre; Nurhan Sutcliffe; David A Isenberg; Fiona Goldblatt; Elizabeth Price; John Hamburger; Andrea Richards; Saaeha Rauz; Marian Regan; Shirley Rigby; Adrian Jones; Diarmuid Mulherin; Ann E Clarke Journal: J Rheumatol Date: 2010-04-01 Impact factor: 4.666
Authors: Xavier Mariette; Philippe Ravaud; Serge Steinfeld; Gabriel Baron; Joelle Goetz; Eric Hachulla; Bernard Combe; Xavier Puéchal; Yvon Pennec; Bernard Sauvezie; Aleth Perdriger; Gilles Hayem; Anne Janin; Jean Sibilia Journal: Arthritis Rheum Date: 2004-04
Authors: Sarah Brown; Nuria Navarro Coy; Costantino Pitzalis; Paul Emery; Sue Pavitt; Janine Gray; Claire Hulme; Frances Hall; Robert Busch; Pete Smith; Luke Dawson; Michele Bombardieri; Ng Wan-Fai; Colin Pease; Elizabeth Price; Nurhan Sutcliffe; Clodagh Woods; Sharon Ruddock; Colin Everett; Catherine Reynolds; Emma Skinner; Ana Poveda-Gallego; John Rout; Iain Macleod; Saaeha Rauz; Simon Bowman Journal: BMC Musculoskelet Disord Date: 2014-01-17 Impact factor: 2.362
Authors: Katherine James; Chimwemwe Chipeta; Antony Parker; Stephen Harding; Simon J Cockell; Colin S Gillespie; Jennifer Hallinan; Francesca Barone; Simon J Bowman; Wan-Fai Ng; Benjamin A Fisher Journal: Rheumatology (Oxford) Date: 2018-07-01 Impact factor: 7.580